Genetic polymorphisms in placental transporters: Implications for fetal drug exposure to oral antidiabetic agents

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 3, 2011, Pages 325-339

  Pollex, Erika K ^a   Hutson, Janine R ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

diabetes in pregnancy; glyburide; metformin; metiglinides; oral antidiabetic agents; placental transport; rosiglitazone; single nucleotide polymorphisms

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; GLIBENCLAMIDE; INDOMETACIN; METFORMIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 3; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 2B1; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER N1; ORGANIC CATION TRANSPORTER N2; PITAVASTATIN; REPAGLINIDE; ROSIGLITAZONE; UNCLASSIFIED DRUG; VERAPAMIL;

DRUG DISPOSITION; DRUG TRANSPORT; GENETIC POLYMORPHISM; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLACENTAL TRANSFER; PREGNANCY DIABETES MELLITUS; PRENATAL DRUG EXPOSURE; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYNCYTIOTROPHOBLAST;

ANIMALS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MATERNAL-FETAL EXCHANGE; MEMBRANE TRANSPORT PROTEINS; PLACENTA; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY;

EID: 79951941382     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.553188     Document Type: Review

References (111)

1. Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol 2006;22:400-10 (Pubitemid 44344445)
2. Feig DS, Razzaq A, Sykora K, et al. Trends in deliveries, prenatal care, and obstetrical complications in women with pregestational diabetes: a population-based study in Ontario, Canada, 1996-2001. Diabetes Care 2006;29:232-5 (Pubitemid 44106497)
3. Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ ethnically diverse population of pregnant women, 1999-2005. Diabetes Care 2008;31:899-904
4. MacFarland A, Abramovich DR, Ewen SW, Pearson CK. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem J 1994;26:417-23 (Pubitemid 24171685)
5. Sugawara I, Akiyama S, Scheper RJ, Itoyama S. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett 1997;112:23-31 (Pubitemid 27067424)
6. Sun M, Kingdom J, Baczyk D, et al. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 2006;27:602-9
7. Gil S, Saura R, Forestier F, Farinotti R. P-glycoprotein expression of the human placenta during pregnancy. Placenta 2005;26:268-70 (Pubitemid 40247016)
8. Atkinson DE, Greenwood SL, Sibley CP, et al. Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am J Physiol Cell Physiol 2003;285:C584-91 (Pubitemid 37022056)
9. Molsa M, Heikkinen T, Hakkola J, et al. Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther 2005;78:123-31 (Pubitemid 41112280)
10. Sudhakaran S, Rayner CR, Li J, et al. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. Br J Clin Pharmacol 2008;65:667-73 (Pubitemid 351535077)
11. Nanovskaya T, Nekhayeva I, Karunaratne N, et al. Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol 2005;69:1869-78 (Pubitemid 40780085)
12. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-8
13. Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-43 (Pubitemid 32472514)
14. Hitzl M, Schaeffeler E, Hocher B, et al. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 2004;14:309-18 (Pubitemid 38638918)
15. Takane H, Kobayashi D, Hirota T, et al. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther 2004;311:1179-87 (Pubitemid 39612726)
16. Hemauer SJ, Nanovskaya TN, Abdel-Rahman SZ, et al. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem Pharmacol 2010;79:921-5
17. Rahi M, Heikkinen T, Hakkola J, et al. Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta. Hum Exp Toxicol 2008;27:65-71 (Pubitemid 351796807)
18. Rahi M, Heikkinen T, Hartter S, et al. Placental transfer of quetiapine in relation to P-glycoprotein activity. J Psychopharmacol 2007;21:751-6 (Pubitemid 47437915)
19. Hemauer SJ, Patrikeeva SL, Nanovskaya TN, et al. Opiates inhibit paclitaxel uptake by P-glycoprotein in preparations of human placental inside-out vesicles. Biochem Pharmacol 2009;78:1272-8
20. Kioka N, Tsubota J, Kakehi Y, et al. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun 1989;162:224-31 (Pubitemid 19185850)
21. Chowbay B, Li H, David M, et al. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005;60:159-71 (Pubitemid 41075901)
22. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359:30-6 (Pubitemid 34119193)
23. Hitzl M, Drescher S, van der Kuip H, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001;11:293-8 (Pubitemid 32537402)
24. Siegsmund M, Brinkmann U, Schaffeler E, et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002;13:1847-54 (Pubitemid 34700609)
25. Evseenko DA, Murthi P, Paxton JW, et al. The ABC transporter BCRP/ ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. FASEB J 2007;21:3592-605 (Pubitemid 350075149)
26. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-64 (Pubitemid 32695041)
27. Meyer zu Schwabedissen HE, Grube M, Dreisbach A, et al. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab Dispos 2006; 34: 524-33.
28. Yeboah D, Sun M, Kingdom J, et al. Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term before and after labor. Can J Physiol Pharmacol 2006;84:1251-8 (Pubitemid 46707373)
29. Mathias AA, Hitti J, Unadkat JD. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol 2005;289:R963-9 (Pubitemid 41397042)
30. Hutson JR, Koren G, Matthews SG. Placental P-glycoprotein and breast cancer resistance protein: influence of polymorphisms on fetal drug exposure and physiology. Placenta 2010;31:351-7
31. Backstrom G, Taipalensuu J, Melhus H, et al. Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci 2003;18:359-64 (Pubitemid 36407696)
32. Bosch TM, Kjellberg LM, Bouwers A, et al. Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. Am J Pharmacogenomics 2005;5:123-31 (Pubitemid 40593438)
33. Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1:611-16
34. Kobayashi D, Ieiri I, Hirota T, et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 2005;33:94-101 (Pubitemid 40023519)
35. Zamber CP, Lamba JK, Yasuda K, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003;13:19-28 (Pubitemid 36135683)
36. Sparreboom A, Gelderblom H, Marsh S, et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C A genotype. Clin Pharmacol Ther 2004;76:38-44 (Pubitemid 38844732)
37. Nagashige M, Ushigome F, Koyabu N, et al. Basal membrane localization of MRP1 in human placental trophoblast. Placenta 2003;24:951-8 (Pubitemid 37321810)
38. St-Pierre MV, Serrano MA, Macias RI, et al. Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 2000;279:R1495-503
39. Pascolo L, Fernetti C, Pirulli D, et al. Effects of maturation on RNA transcription and protein expression of four MRP genes in human placenta and in BeWo cells. Biochem Biophys Res Commun 2003;303:259-65 (Pubitemid 36338234)
40. Conrad S, Kauffmann HM, Ito K, et al. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J Hum Genet 2001;46:656-63 (Pubitemid 33134743)
41. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-62 (Pubitemid 43739516)
42. Yin JY, Huang Q, Yang Y, et al. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 2009;19:206-16
43. Letourneau IJ, Deeley RG, Cole SP. Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genomics 2005;15:647-57 (Pubitemid 41113337)
44. Leslie EM, Letourneau IJ, Deeley RG, Cole SP. Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ ABCC1). Biochemistry 2003;42:5214-24 (Pubitemid 36560417)
45. Conrad S, Kauffmann HM, Ito K, et al. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 2002;12:321-30 (Pubitemid 34620660)
46. Wang Z, Wang B, Tang K, et al. A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection. Hum Mol Genet 2005;14:2075-87 (Pubitemid 41418043)
47. Oselin K, Mrozikiewicz PM, Gaikovitch E, et al. Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. Eur J Clin Pharmacol 2003;59:347-50 (Pubitemid 37100355)
48. Azzaroli F, Mennone A, Feletti V, et al. Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. Aliment Pharmacol Ther 2007;26:1139-46 (Pubitemid 47480961)
49. Lang T, Hitzl M, Burk O, et al. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 2004;14:155-64 (Pubitemid 38373109)
50. Doerfel C, Rump A, Sauerbrey A, et al. In acute leukemia, the polymorphism -211C T in the promoter region of the multidrug resistance-associated protein 3 (MRP3) does not determine the expression level of the gene [letter]. Pharmacogenet Genomics 2006;16(2):149-50 (Pubitemid 43145683)
51. Gradhand U, Tegude H, Burk O, et al. Functional analysis of the polymorphism -211C T in the regulatory region of the human ABCC3 gene. Life Sci 2007;80:1490-4 (Pubitemid 46399747)
52. Lee YM, Cui Y, Konig J, et al. Identification and functional characterization of the natural variant MRP3-Arg1297. His of human multidrug resistance protein 3 (MRP3/ABCC3). Pharmacogenetics 2004;14:213-23 (Pubitemid 38530513)
53. Kobayashi K, Ito K, Takada T, et al. Functional analysis of nonsynonymous single nucleotide polymorphism type ATP-binding cassette transmembrane transporter subfamily C member 3. Pharmacogenet Genomics 2008;18:823-33
54. Patel P, Weerasekera N, Hitchins M, et al. Semi quantitative expression analysis of MDR3, FIC1, BSEP, OATP-A, OATP-C, OATP-D, OATP-E and NTCP gene transcripts in 1st and 3rd trimester human placenta. Placenta 2003;24:39-44 (Pubitemid 37184694)
55. Serrano MA, Macias RI, Briz O, et al. Expression in human trophoblast and choriocarcinoma cell lines, BeWo, Jeg-3 and JAr of genes involved in the hepatobiliary-like excretory function of the placenta. Placenta 2007;28:107-17 (Pubitemid 44914531)
56. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158:693-705
57. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 2009;5:703-29
58. St-Pierre MV, Hagenbuch B, Ugele B, et al. Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J Clin Endocrinol Metab 2002;87:1856-63 (Pubitemid 34615280)
59. Grube M, Reuther S, Meyer Zu Schwabedissen H, et al. Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta. Drug Metab Dispos 2007;35:30-5 (Pubitemid 46036473)
60. Mougey EB, Feng H, Castro M, et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009;19:129-38
61. Aoki M, Terada T, Ogasawara K, et al. Impact of regulatory polymorphisms in organic anion transporter genes in the human liver. Pharmacogenet Genomics 2009;19:647-56
62. Kekuda R, Prasad PD, Wu X, et al. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem 1998;273:15971-9 (Pubitemid 28311362)
63. Sata R, Ohtani H, Tsujimoto M, et al. Functional analysis of organic cation transporter 3 expressed in human placenta. J Pharmacol Exp Ther 2005;315:888-95 (Pubitemid 41500755)
64. Ganapathy V, Zhuang L, Devoe LD, Prasad PD. Expression of OCTN1 in placental brush border membrane and its interaction with antidepressants. J Soc Gynecol Invest 2005;12:180A
65. Roque AS, Prasad PD, Bhatia JS, et al. Sodium-dependent high-affinity binding of carnitine to human placental brush border membranes. Biochim Biophys Acta 1996;1282:274-82 (Pubitemid 26249253)
66. Lahjouji K, Elimrani I, Lafond J, et al. L-Carnitine transport in human placental brush-border membranes is mediated by the sodium-dependent organic cation transporter OCTN2. Am J Physiol Cell Physiol 2004;287:C263-9 (Pubitemid 38955216)
67. Grube M, Schwabedissen HM, Draber K, et al. Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. Drug Metab Dispos 2005;33:31-7 (Pubitemid 40023511)
68. Nies AT, Koepsell H, Winter S, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009;50:1227-40
69. Lazar A, Walitza S, Jetter A, et al. Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol 2008;11:35-48
70. Kawasaki Y, Kato Y, Sai Y, Tsuji A. Functional characterization of human organic cation transporter OCTN1 single nucleotide polymorphisms in the Japanese population. J Pharm Sci 2004;93:2920-6 (Pubitemid 39657796)
71. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004;36:471-5 (Pubitemid 38620030)
72. Urban TJ, Brown C, Castro RA, et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther 2008;83:416-21 (Pubitemid 351272627)
73. Koizumi A, Nozaki J, Ohura T, et al. Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency. Hum Mol Genet 1999;8:2247-54 (Pubitemid 29525340)
74. Tahara H, Yee SW, Urban TJ, et al. Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5). J Pharmacol Exp Ther 2009;329:262-71
75. Urban TJ, Gallagher RC, Brown C, et al. Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5). Mol Pharmacol 2006;70:1602-11
76. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9 (Pubitemid 126537875)
77. Buchanan TA, Metzger BE, Freinkel N, Bergman RN. Insulin sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. Am J Obstet Gynecol 1990;162:1008-14 (Pubitemid 20155423)
78. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71 (Pubitemid 26177181)
79. Nanovskaya TN, Nekhayeva IA, Patrikeeva SL, et al. Transfer of metformin across the dually perfused human placental lobule. Am J Obstet Gynecol 2006;195:1081-5 (Pubitemid 44430086)
80. Vanky E, Zahlsen K, Spigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril 2005;83:1575-8 (Pubitemid 40615847)
81. Eyal S, Easterling TR, Carr D, et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos 2010;38:833-40
82. Kovo M, Haroutiunian S, Feldman N, et al. Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model. Eur J Obstet Gynecol Reprod Biol 2008;136:29-33
83. Kovo M, Kogman N, Ovadia O, et al. Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model. Prenat Diagn 2008;28:544-8 (Pubitemid 351946958)
84. Hemauer SJ, Patrikeeva SL, Nanovskaya TN, et al. Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol 2010;202:383.e1-7
85. Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005;20:379-86
86. Tertti K, Ekblad U, Heikkinen T, et al. The role of organic cation transporters (OCTs) in the transfer of metformin in the dually perfused human placenta. Eur J Pharm Sci 2010;39:76-81
87. Choi MK, Jin QR, Jin HE, et al. Effects of tetraalkylammonium compounds with different affinities for organic cation transporters on the pharmacokinetics of metformin. Biopharm Drug Dispos 2007;28:501-10
88. Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009;86:299-306
89. Kalliokoski A, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol 2010;107:775-81
90. Kraemer J, Klein J, Lubetsky A, Koren G. Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol 2006;195:270-4 (Pubitemid 43927503)
91. Zhou L, Naraharisetti SB, Wang H, et al. The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol 2008;73:949-59 (Pubitemid 351397899)
92. Gedeon C, Behravan J, Koren G, Piquette-Miller M. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta 2006;27:1096-102 (Pubitemid 44400512)
93. Gedeon C, Anger G, Lubetsky A, et al. Investigating the potential role of multi-drug resistance protein (MRP) transporters in fetal to maternal glyburide efflux in the human placenta. J Obstet Gynaecol 2008;28:485-9
94. Pollex E, Lubetsky A, Koren G. The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta 2008;29:743-7
95. Satoh H, Yamashita F, Tsujimoto M, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005;33:518-23 (Pubitemid 40393194)
96. Pollex EK, Anger G, Hutson J, et al. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism. Drug Metab Dispos 2010;38:740-4
97. Haddad GF, Jodicke C, Thomas MA, et al. Case series of rosiglitazone used during the first trimester of pregnancy. Reprod Toxicol 2008;26:183-4
98. Chan LY, Yeung JH, Lau TK. Placental transfer of rosiglitazone in the first trimester of human pregnancy. Fertil Steril 2005;83:955-8
99. Nanovskaya TN, Patrikeeva S, Hemauer S, et al. Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide. J Matern Fetal Neonatal Med 2008;21:197-207 (Pubitemid 351302429)
100. Bachmakov I, Glaeser H, Fromm MF, Konig J. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes 2008;57:1463-9
101. Chang C, Pang KS, Swaan PW, Ekins S. Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther 2005;314:533-41 (Pubitemid 41043833)
102. Aquilante CL, Bushman LR, Knutsen SD, et al. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum Genomics 2008;3:7-16
103. Mollar-Puchades MA, Martin-Cortes A, Perez-Calvo A, Diaz-Garcia C. Use of repaglinide on a pregnant woman during embryogenesis. Diabetes Obes Metab 2007;9:146-7 (Pubitemid 44921058)
104. Napoli A, Ciampa F, Colatrella A, Fallucca F. Use of repaglinide during the first weeks of pregnancy in two type 2 diabetic women. Diabetes Care 2006;29:2326-7 (Pubitemid 44899877)
105. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol 2008;48:311-21 (Pubitemid 351257770)
106. Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005;77:468-78 (Pubitemid 40824960)
107. Zhang W, He YJ, Han CT, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol 2006;62:567-72 (Pubitemid 44571578)
108. Myllynen P, Immonen E, Kummu M, Vahakangas K. Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues. Expert Opin Drug Metab Toxicol 2009;5:1483-99
109. Petrovic V, Wang JH, Piquette-Miller M. Effect of endotoxin on the expression of placental drug transporters and glyburide disposition in pregnant rats. Drug Metab Dispos 2008;36:1944-50
110. Williams JA, Johnson K, Paulauskis J, Cook J. So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J Clin Pharmacol 2006;46:258-64 (Pubitemid 43260312)
111. Gedeon C, Anger G, Piquette-Miller M, Koren G. Breast cancer resistance protein: mediating the trans-placental transfer of glyburide across the human placenta. Placenta 2008;29:39-43